Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design

Area of Science:

• Structural biology
• Virology
• Drug discovery

Background:

• Retroviral proteases (PRs) are validated drug targets, exemplified by successful HIV-1 protease inhibitors for AIDS treatment.
• Understanding retroviral protease structures is crucial for developing targeted therapies.

Purpose of the Study:

• To determine the structure of human T cell leukemia virus type 1 protease (HTLV-1 PR) in complex with a substrate-based inhibitor.
• To identify structural features of HTLV-1 PR that may confer resistance to existing anti-HIV drugs.
• To provide a structural basis for designing novel anticancer therapies targeting HTLV-1 PR.

Main Methods:

• X-ray crystallography was used to determine the 3D structure of the HTLV-1 PR-inhibitor complex.
• Structural comparisons were made between HTLV-1 PR and other retroviral proteases, particularly HIV-1 PR.
• Analysis focused on loop regions, including the functionally important flaps.

Main Results:

• The structure of HTLV-1 PR complexed with a substrate-based inhibitor (spanning subsites P5 to P5') was elucidated.
• HTLV-1 PR shares an overall fold with other retroviral proteases but exhibits significant structural variations in loop areas, including the flaps.
• Key residues potentially responsible for HTLV-1 PR resistance to anti-HIV drugs were identified.

Conclusions:

• The structural insights into HTLV-1 PR can inform the development of novel antileukemia drugs.
• Knowledge gained from anti-HIV drug development, especially regarding drug resistance, can aid in designing HTLV-1 PR inhibitors.
• The determined structure serves as a foundation for developing anticancer therapies targeting HTLV-1 PR.